Cardiac ' Shrinkage ' on Sacubitril/Valsartan May Rival CRT in HF Cardiac ' Shrinkage ' on Sacubitril/Valsartan May Rival CRT in HF

LV volumes fell and LVEF rose, often 10 points or more, after a year on the ARNI. That approaches gains on cardiac resynchronization therapy,"the reverse-remodeling champion," a researcher notes.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news